Compounds > capecitabine
Page last updated: 2024-08-24

capecitabine and Adrenal Cortex Cancer

capecitabine has been researched along with Adrenal Cortex Cancer in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Canu, L; De Filpo, G; Mannelli, M1
Ambrosini, R; Berruti, A; Cosentini, D; Ferrari, L; Ferrari, VD; Grisanti, S; Laganà, M; Lazzari, B; Morandi, A; Sigala, S; Volta, AD1
Blesius, A; Ciccolini, J; Duffaud, F; Dupuis, C; Fanciullino, R; Frances, N; Giacometti, S; Iliadis, A; Mercier, C; Padovani, L; Yang, CG1
Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Quinkler, M; Ritter, C; Wortmann, S1
Angeli, A; Badalamenti, G; Berruti, A; Daffara, F; De Francia, S; Del Buono, S; Dogliotti, L; Ferrero, A; Intrivici, C; Kalomirakis, E; Papotti, M; Priola, A; Ratti, R; Santini, D; Sperone, P; Terzolo, M; Vincenzi, B; Volante, M; Zaggia, B1

Reviews

1 review(s) available for capecitabine and Adrenal Cortex Cancer

ArticleYear
Adrenocortical carcinoma: current treatment options.
    Current opinion in oncology, 2021, Volume: 33, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Mitotane; Randomized Controlled Trials as Topic

2021

Trials

2 trial(s) available for capecitabine and Adrenal Cortex Cancer

ArticleYear
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.
    European journal of endocrinology, 2010, Volume: 162, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Salvage Therapy; Severity of Illness Index; Survival Rate; Treatment Failure; Vascular Endothelial Growth Factor A

2010
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
    Endocrine-related cancer, 2010, Volume: 17, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Mucositis; Thrombocytopenia; Treatment Outcome

2010

Other Studies

2 other study(ies) available for capecitabine and Adrenal Cortex Cancer

ArticleYear
Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult

2021
Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6

    Topics: Adrenal Cortex Neoplasms; Antimetabolites, Antineoplastic; Capecitabine; Cytidine Deaminase; Deoxycytidine; Female; Fluorouracil; Humans; Metabolic Clearance Rate; Polymorphism, Genetic; Young Adult

2009